Beam Therapeutics Pronounces New Knowledge from BEACON Section 1/2 Medical Trial of BEAM-101 in Sickle Cell Illness at American Society of Hematology (ASH) Annual Assembly By Investing.com
All Seven Sufferers Handled with BEAM-101 Achieved Hemoglobin F (HbF) Induction of…
Trinity Capital Inc. Offers $40 Million in Development Capital to Beam Advantages By Investing.com
PHOENIX, Oct. 10, 2024 /PRNewswire/ -- Trinity Capital Inc . (NASDAQ:…
